



(11) **EP 1 755 650 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 38/21 ^(2006.01) **A61K 9/16** ^(2006.01)
A61K 9/00 ^(2006.01) **A61K 47/18** ^(2006.01)

(48) Corrigendum issued on:
15.10.2008 Bulletin 2008/42

(86) International application number:
PCT/US2005/017914

(45) Date of publication and mention
of the grant of the patent:
09.07.2008 Bulletin 2008/28

(87) International publication number:
WO 2005/115333 (08.12.2005 Gazette 2005/49)

(21) Application number: **05753131.1**

(22) Date of filing: **23.05.2005**

(54) **A BIOMOLECULE-CONTAINING SUSPENSION FORMULATION OF INCREASED STABILITY DELIVERABLE VIA AN IMPLANTABLE DELIVERY DEVICE**

EINE BIOMOLEKÜLE ENTHALTENDE SUSPENSIONSFORMULIERUNG VON ERHÖHTER STABILITÄT - FREISETZBAR ÜBER EIN IMPLANTIERBARES HILFSMITTEL

UNE SUSPENSION CONTENANT UNE BIOMOLÉCULE - D'UNE STABILITÉ AUGMENTÉE ET D'UNE ADMINISTRATION PAR UN DISPOSITIF IMPLANTABLE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **25.05.2004 US 574662 P**
03.02.2005 US 650226 P

(43) Date of publication of application:
28.02.2007 Bulletin 2007/09

(73) Proprietor: **Intarcia Therapeutics, Inc**
Hayward CA 94545 (US)

(72) Inventors:
• **JUNNARKAR, Gunjan**
Palo Alto, California 94303 (US)

- **DESJARDIN, Michael A.**
Sunnyvale, CA 94087 (US)
- **LIU, Kui**
Redwood City, CA 94065 (US)
- **LI, Zengji**
San Ramon, CA 94583 (US)

(74) Representative: **Walton, Seán Malcolm et al**
Mewburn Ellis LLP
York House
23 Kingsway
London WC2B 6HP (GB)

(56) References cited:
WO-A-20/04056338 **US-A- 5 219 572**
US-A1- 2003 044 467 **US-A1- 2003 059 376**
US-A1- 2003 215 515 **US-B1- 6 468 961**

EP 1 755 650 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).